Blueprint’s most recently approved drug is Ayvakit, which the US Food and Drug Administration approved in 2020 to treat gastrointestinal stromal tumors, in 2021 to treat advanced systemic mastocytosis, and in 2023 to treat indolent systemic mastocytosis (ISM). It is the only approved drug to specifically treat ISM, which is cautilized by too many mast cells building up in the body.
Sanofi will acquire Ayvakit in the deal, as well as elenestinib, a prospective systemic mastocytosis treatment currently in phase 2/3 trials, and BLU-808, a prospective KIT inhibitor for an unspecified range of inflammatory diseases.
“While we expected [Blueprint] was likely to be on the strategic radar of large pharma given Ayvakit’s blockbuster trajectory and recent guidance revisions, this deal happened sooner than anticipated,” declare analysts at Leerink Partners in a note to investors. They declare that a competitor, Cogent Biosciences, is planning on reading out results for its own ISM drug, bezuclastinib, in July. It is possible, they declare, that this readout would have cautilized investors to speculate about the ISM market, which may have boosted the value of Blueprint’s shares, incentivizing Sanofi to close the deal before that happened.
Leerink analyst David Risinger also declares in a different note that Sanofi “will required to deliver on its plans to find and treat more patients. In addition, it is critical, in our view, that [Blueprint]’s pipeline delivers blockbuster revenue over the long term.”
Leave a Reply